Search alternatives:
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 50 ns (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
5 ng » 5 mg (Expand Search), 5 g (Expand Search), 5 nm (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 50 ns (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
5 ng » 5 mg (Expand Search), 5 g (Expand Search), 5 nm (Expand Search)
-
121
-
122
-
123
-
124
-
125
-
126
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
127
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
128
-
129
-
130
-
131
-
132
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
-
133
-
134
Predicting pattern diversity decreases as a function of and .
Published 2025“…(a) and (b): Average negative predictive value for and , respectively for and . …”
-
135
-
136
Inhibition of pan- and HDAC isoform activities.
Published 2024“…Pharmacokinetic evaluation demonstrates an area under the curve (AUC) of 5227.55 ng/ml × h with an elimination half-life of 1.26 h following intravenous administration in a rat model. …”
-
137
-
138
-
139
-
140